News

DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
DATROWAY® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with ...
pharmaphorum8d
AZ, Daiichi get EU okay for breast cancer drug Datroway
AstraZeneca and Daiichi Sankyo have claimed approval from the European Commission for their TROP2-directed antibody-drug ...
PMLive6d
AstraZeneca/Daiichi Sankyo’s Datroway approved by EC to treat breast cancer
AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been approved by the European Commission (EC) for ...
Seeking Alpha8d
DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
First approval in the EU for Daiichi Sankyo and AstraZeneca’s DATROWAY based on TROPION-Breast01 trial showing 37% reduction in the risk of disease progression or death versus chemotherapy ...
AFP8d
DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
DATROWAY ® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative ...
The Pharma Letter8d
First approval in the EU for Daiichi Sankyo and AstraZeneca’s Datroway
Datroway (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with ...
AstraZeneca (LSE:AZN) Gains EU Approval For Breast Cancer Treatment DATROWAY
AstraZeneca (LSE:AZN) saw its share price decline by 3.5% in the last quarter, a period marked by several key developments, ...